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ABSTRACT 
Obesity is accompanied by a low-grade inflammation state, characterized by increased 
of pro-inflammatory cytokines levels as tumor necrosis factor alpha (TNFα) and 
interleukin-1 beta (IL-1β). In this regard, exists a lack of studies in hepatic tissue about 
the role of TNFα receptor 1 (TNFR1) in the context of obesity and insulin resistance 
during the progression of non-alcoholic fatty liver disease (NAFLD). The aim of this 
work was to evaluate the effects of high caloric feeding (HFD) (40% fat, during 16 
weeks) on TNFR1 knock-out (TNFR1KO) and Wild Type (WT) mice on liver 
inflammation induced-apoptosis, insulin resistance, hepatic lipid accumulation and its 
progression towards non-alcoholic steatohepatitis (NASH). Mechanisms involved in 
HFD-derived IL-1β release and impairment of insulin signaling are still unknown, so we 
determined whether IL-1β affects liver insulin sensitivity and apoptosis through 
TNFR1-dependent pathways. We showed that knocking-out TNFR1 induces an 
enhanced IL-1β plasmatic release upon HFD feed. This was correlated to higher hepatic 
and epididymal white adipose tissue (eWAT) mRNA levels. In vivo and in vitro assays 
confirmed an impairment in hepatic insulin signaling, in part due to IL-1β-induced 
decrease of AKT activation and diminution of IRS1 levels, followed by an increase in 
inflammation, macrophage (resident and recruited) accumulation, hepatocyte apoptotic 
process and finally hepatic damage. Additionally, TNFR1 KO mice displayed higher 
levels of pro-fibrogenic markers. TNFR1 signaling disruption upon a HFD leads to an 
accelerated progression from simple steatosis towards a more severe phenotype with 
many NASH features, pointing out a key role of TNFR1 in NAFLD progression. 
Keywords: High Fat Diet; TNFR1; non alcoholic liver disease; Il-1Beta; insulin 
resistance; inflammation, IRS1, p-AKT  
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1. INTRODUCTION 
Obesity results from progressive loss of the homeostatic control of food intake 
and energy expenditure [1]. Obese individuals develop resistance to the cellular actions 
of insulin, characterized by an impaired ability of insulin to inhibit glucose output from 
the liver and to promote glucose uptake in fat and muscle. Obesity and insulin resistance 
are accompanied by a low-grade inflammation state, characterized by increased of pro-
inflammatory cytokines in the circulation and tissues. Chronic tissue inflammation has 
been identified as a major contributor to the decreased insulin sensitivity in obesity [2]. 
The origin of this inflammation could be related to adipose tissue expansion because the 
expression of pro-inflammatory cytokines including TNFα and IL-1β are increased in 
this tissue in the obese state. In this regard, increased macrophage population in adipose 
tissue is thought to be responsible for this elevated production of cytokines [3,4]. 
The pro-inflammatory cytokine TNFα plays a key role in a wide variety of 
physiological processes, including inflammation, proliferation and programmed cell 
death. TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) are the two main 
transducers of the TNFα signals in most cells and tissues [5]. Transducing TNFα signals 
through either receptor results in the activation of inflammatory genes transcription by 
Nuclear Factor kappa B (NFκB) and Activator Protein 1 (AP-1) [6]. In addition, pro-
apoptotic stimulus can be induced by the binding of TNFα to TNFR1 [5,6], that leads to 
caspase-8 activation, resulting in cleavage of caspase-3 triggering apoptotic cell death. 
The role of TNFα in the context of obesity and insulin resistance has been 
thoroughly explored for many years. However, the participation of each TNFα receptor 
in obesity-induced insulin resistance had been less studied, existing still controversy on 
the importance of this inflammatory pathway in the setting of insulin resistance and 
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obesity-related diseases. While several ‘‘loss-of-function’’ studies reported a partial 
protection against the development of insulin resistance in mice lacking TNFα [7,8]; 
other studies suggested that TNFR1 has no role [9] or even a protective one [10] against 
the development of insulin-resistance. Although blocking TNFα improved insulin 
resistance in rodents, neutralizing antibodies against TNFα did not significantly improve 
insulin sensitivity in obese type 2 diabetic patients [11]. On the other hand, it was 
reported that TNFR1 “gain of function” mutation aggravates nonalcoholic fatty liver 
disease hallmarks [12]. Even more, and specifically in models of metabolic disorders, it 
was reported that when are knocking out the two receptors separately, only the absence 
of TNFR1 showed to be relevant in energetic homeostasis [8]. 
Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat 
accumulates in the liver of a patient without a history of alcohol abuse and it has 
become the most common form of liver disease in developed countries. It covers a wide 
spectrum of hepatic damage in which steatosis with inflammation progresses to non-
alcoholic steatohepatitis (NASH), fibrosis and cirrhosis, and hepatocellular carcinoma. 
Although, NAFLD is closely associated with obesity, insulin resistance and metabolic 
syndrome, the pathogenesis of NAFLD has not been fully elucidated [13,14]. Assuming 
the discrepancy of published results and the lack of studies in hepatic tissues about the 
role of TNFR1 in the context of obesity and insulin resistance in the progression of non-
alcoholic fatty liver disease, we first decided to evaluate the effects of high caloric 
feeding (HFD) on TNFR1 knock-out mice and its association with liver inflammation 
induced-apoptosis, insulin resistance, steatosis and its progression towards NASH.  
Whereas the implication of TNFα in insulin resistance is well documented, little 
is known about the role of IL-1β. Recent studies demonstrate that expression of IL-1β is 
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increased in adipose tissue of both obese rodents and humans [15].  Since the 
mechanisms involved in the induction of IL-1β release by a HFD are still unknown, as 
well as the associated alteration of insulin signaling and apoptosis, we then determined 
whether IL-1β affects insulin sensitivity and liver apoptosis through TNFR1-dependent 
pathways. Here, we showed that knocking out TNFR1 induces IL-1β release which 
enhances liver insulin resistance followed by an increase in liver inflammation and the 
progression from simple steatosis towards a phenotype with NASH features. 
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2. RESEARCH DESIGN AND METHODS 
2.1. Experimental Model and Feeding Protocols 
Knockout C57BL/6-Tnfrsf1atm1Imx/J (TNFR1 KO) mice (20-25 g body weight; 
6-8 weeks) originally obtained from The Jackson Laboratory and gently provided by Dr. 
Silvia Di Genaro were used in this study along with corresponding age-matched wild-
type (WT) mice. Male C57BL/6 mice (WT), 6–8 weeks of age, were provided by the 
School of Medicine, National University of Rosario. Mice were maintained at the 
animal facilities of the School of Biochemistry of National University of Rosario. The 
animals were maintained in light/ dark (12 h light/12 h dark), temperature (22 °C) and 
humidity- controlled rooms with free access to drinking water. Animals received human 
care according to criteria outlined in the “Guide for the Care and Use of Laboratory 
Animals” (National Research Council, Washington D.C.: National Academy Press, 
1996). All the experimental protocols were performed according to the Regulation for 
the Care and Use of Laboratory Animals (Expedient 6109/012 E.C. Resolution 267/02) 
and approved by the Institutional Animal Use Committee of the National University of 
Rosario, Argentina. 
WT and TNFR1 KO mice were fed with regular chow diet (CHOW)(GEPSA, 
http://www.gepsa.com) or a 40% high-fat diet (HFD) (Composition in Supplementary 
table 1) ad libitum for 16 weeks. During HFD treatment, body weight and food were 
recorded every ten days .Upon 16 weeks of treatment, animals were euthanized; blood 
was obtained by cardiac puncture [16], and plasma prepared for biochemical parameters 
determination. Liver tissues and eWAT, were snap-frozen in liquid nitrogen and stored 
at -80°C. Glucose, triglycerides, cholesterol and transaminases AST and ALT were 
assayed spectrophotometrically in plasma with specific kits from Wiener Lab (Wiener 
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Lab, Rosario, Argentina). Samples of liver tissue were fixed in 4% buffered formalin 
for paraffin preparation and then were used for histopathology assessment [17]. For in 
vivo insulin signaling studies, another set of O/N fasted animals were i.p. injected with 
0.75 units/kg b.w. of human recombinant insulin and euthanized 15 min later [18]. 
 
2.2 Data analysis 
Data are expressed as means ± s.e.m. Statistical significance was determined by 
Student's t-test or the one-way analysis of variance followed by Tukey's test. Analysis 
was performed by using the statistical software GraphPad Prism 5. A p<0.05 was 
considered statistically significant.  
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3. RESULTS 
3.1 TNFR1 disruption promotes fat liver accumulation 
First, in order to assess the diet-induced obesity model, weight gain curve was 
performed periodically determining the weight of the animals for 16 weeks (Figure 1A). 
As it was previously described, HFD-WT show an increase in body mass compared to 
CHOW-WT. However, KO mice showed a significantly lower gain body weight when 
submitted to high fat diet feeding. This protection from diet induced-obesity found in 
TNFR1 KO mice was independent of food intake, being the relative food intake of 
TNFR1 KO not different of WT food intake on either diet (Figure 1B). Table 1 shows 
plasma biochemical assays. Measurement of plasma glucose, cholesterol and 
triglycerides levels demonstrated that HFD-KO mice showed lower levels of these 
parameters when compared to HFD-WT mice. In order to analyze the effect of TNFR1 
KO phenotype on peripheral response to insulin we performed the GTT and ITT tests. 
Glucose tolerance was modified in TNFR1-KO mice showing higher glucose plasma 
levels than WT mice (Figure 1C). In contrast, intraperitoneal injection of insulin caused 
a more rapid and pronounced reduction in blood glucose levels in wild type control 
mice when compared to the HFD-fed mice, observing a similar pattern in KO mice 
when comparing CHOW and HFD-fed animals (Figure 1C). In these sense, KO mice 
did not increase insulin plasmatic levels during HF feeding (Table 1). In contrast, HFD 
fed resulted in a mild elevation of plasma ALT and AST in KO phenotype mice 
compared with their wild type counter mates (Figure 1D). 
It is known that chronic HF feeding causes accumulation of lipids in the liver, 
leading to fatty liver disease [19]. To determine whether TNFR1 was implicated in this 
process, hepatic lipids were evaluated. Disruption of TNFR1 signaling induced a 
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marked steatotic phenotype in HFD-KO mice, with accumulation of fat vacuoles 
(Figure 1E). In line with this, HFD-KO mice exhibited increased triglyceride content in 
the liver when compared to HFD-WT (Figure 1F). 
3.2 Disruption of TNFR1 signaling increases macrophage liver infiltration 
In the progression of nonalcoholic liver disease, steatosis and elevated serum 
ALT levels are followed by inflammation. [20] Hepatic recruitment of macrophages 
promotes nonalcoholic steatohepatitis through CCR2 (C-C chemokine receptor type 2) 
increased expression [21]. Here, we focused our study specifically on the effect that diet 
has on TNFR1 knock-out phenotype. We observed higher content of hepatic 
inflammatory infiltrate in HFD-KO mice respect to HFD-WT mice, when were 
evaluated by histological analysis (Figure 2A). Next, we isolated hepatic non-
parenchymal cells (NPCs) from HF-fed mouse livers in order to define the 
characteristics of innate immune cells, followed by FACS analysis. As illustrated in 
Figure 2B, livers from TNFR1-KO mice showed an increase in CD45
+
F4/80
+
 cells 
suggesting an augmented liver accumulation of macrophages in mice lacking TNFR1. 
To further assess the different macrophage populations we analyzed F4/80
+
 population 
cells. We observed an increment in CD45
+
F4/80
high 
population, which correlates with 
increased levels of resident hepatic macrophages in HFD KO mice when compared to 
WT HFD-fed mice (Figure 2C). The same behavior was observed in recruited hepatic 
macrophages (CD45
+
F4/80
low
 population) levels (Figure 2C). In this sense, 
macrophages isolated from KO mice showed an increase in a classical pro-
inflammatory activation state (M1), determined by an increase in CD45
+
F4/80
+
CD11c
+
 
cells when compared to HF-fed-WT (Figure 2D). Also, the number of CCR2-expressing 
cells was higher in TNFR1-KO suggesting not only a pro-inflammatory profile of the 
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resident macrophages but also a greater recruitment of pro-inflammatory macrophages 
to the liver (Figure 2E).  
3.3 TNFR1-KO mice show a decreased hepatic insulin signaling 
Inflammation, hepatic lipid and glucose metabolism are closely related in the 
pathogenesis of liver disease, linking insulin resistance to the development of hepatic 
steatosis and the progression to steatohepatitis [22,23]. We analyzed the insulin 
activation pathways in the liver. Ours results showed a decrease in p-AKT protein 
expression in the liver of HFD-KO mice when compared to HFD-WT mice (Figure 3A). 
The analysis of insulin receptor phosphorylation (p-IR) showed a similar behavior to 
that observed for p-AKT (Figure 3B). Low insulin receptor substrate 1 (IRS1) mRNA 
expression and protein levels have been linked to the development of insulin resistance 
associated to inflammation [24,25]. In this regards, IRS1 protein expression tend to 
decrease in HF-fed-KO compared to HF-fed-WT mice being in agreement with the 
activation patterns of p-AKT and p-IR (Figure 3C). In addition, we measured mRNA 
levels of Irs1 in liver and eWAT observing lower levels in livers of HFD-KO group 
comparing to HFD-WT. mRNA levels of Irs1 in eWAT did not show differences 
(Figure 3C). Taken together, these data demonstrate that, despite no change in systemic 
sensitivity to insulin, HF-fed-KO mice have an impaired hepatic insulin action. Given 
the close relation between inflammation and ERK as one mediator in insulin resistance 
we measured its phosphorylated levels, observing an increase in its expression in HFD-
KO mice compared to HFD-WT (Figure 3D). In addition, to corroborate in vivo 
findings, we performed in vitro studies in isolated hepatocytes from mice of all 
experimental groups. Ours results demonstrated that on a HFD condition, lower 
expressions of p-AKT was observed in TNFR1KO mice (Figure 3E).  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
10 
 
3.4 TNFR1 deficiency promotes liver apoptosis 
It is well established the role of TNFR1 in the development of apoptosis in 
different tissues. Insulin resistance increased hepatocyte apoptosis is now considered as 
an important factor contributing to liver disease progression [24]. In this connection, we 
analyzed if apoptosis process was modified in HF-fed mice lacking TNFR1. As shown 
in Figure 4, apoptotic index (AI) and caspase-3 activity were increased in HFD-WT 
when compared to chow fed mice. Analyzing the apoptotic process in mice lacking 
TNFR1 we found that HF-fed mice exhibited a significantly increase of Apoptotic index 
and caspase-3 activity (Figure 4A and 4B). This increase observed in HFD-KO was 
confirmed by TUNEL assay (Figure 4C). Consistently, we observed an increase in the 
BAX/BCL-xL ratio in HFD-KO mice (Figure 4D). In this regard, insulin resistance was 
associated to an augmented hepatic apoptotic state [24]. To support this fact in our 
model, we determined the levels of BAD protein in hepatic mitochondrial fractions. The 
pro-apoptotic BAD protein, a member of the BCL-2 family that is involved in the 
regulation of apoptosis, is inactivated by a mechanism dependent of AKT 
phosphorylation. Increase of p-AKT levels produce greater BAD phosphorylation (and 
lower BAD translocation into the mitochondria), promoting cell survival instead of 
apoptosis. On HF diet condition, a significant increase in BAD localization in 
mitochondrial fraction was observed when compared to levels observed on CHOW diet 
condition. In addition, KO mice fed with HFD exhibited a greater mitochondrial 
localization of BAD, which could be associated to lower AKT activation, and so 
promoting apoptotic cell death (Figure 4E). To corroborate these results, and using flow 
cytometry analysis, we observed an increase in hipoploide (a hallmark of apoptotic 
cells) percentage of cells in HFD-KO mice when compared to HFD-WT mice (Figure 
4F). 
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3.5 TNFR1-KO mice exhibit features of a pro-inflammatory state 
Given the increase of macrophage liver infiltration in KO HF-fed mice, we 
decided to examine the expression of several inflammation makers. Plasma cytokine 
levels demonstrated that HF feeding induced the release of IL-1β. In this regard, we 
found that TNFR1-KO mice showed significantly higher levels of IL-1β when 
compared to WT mice (Figure 5A). In this sense, HF-fed-KO mice showed a 7-fold 
increase in IL-1β plasma levels when compared to HF-fed-WT mice, a more discrete 
increase in IL-6, while TNF plasma levels remain unchanged between HF-fed animals. 
In order to identify a possible source of IL-1β we determined hepatic and eWAT mRNA 
expression of pro-inflammatory cytokines in HF-fed mice. We found that HF-fed-KO 
mice showed an increased expression of Il1β, Il6 and Tnfα both in liver and eWAT 
when compared to HF-fed-WT mice (Figure 5B and 5C). Furthermore, the expression 
of IL-1β receptor was increased in plasmatic membrane of liver from mice lacking 
TNFR1 fed the HFD, suggesting that the liver could be acting both as the source and 
target tissue for IL-β1 (Figure 5D). Macrophages express high levels of the innate 
immune Toll-like receptor 4 (TLR 4), and this receptor has been implicated as an 
important player in chronic low-grade inflammation associated to obesity [26]. We 
found that TLR4 protein expression was increased in HFD-KO mice when compared to 
HFD-WT mice in plasmatic membrane of total livers. According with our data, 
activation of TLR4 signaling leads to the generation of pro-inflammatory cytokines as 
IL-1 (Figure 5E). 
3.6 Apoptosis and insulin resistance in HFD-KO mice are IL-1-dependent 
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In order to investigate whether IL-1β is involved in the development of insulin 
resistance in HF-fed-KO mice, we performed in vitro studies in isolated hepatocytes 
from WT and TNFR1 KO mice. Hepatocytes were pretreated with 10 or 50 ng/ml of IL-
1β for 24 hours, and in the case of insulin signaling studies, followed by 10 nM or 50 
nM insulin for 7 min. As shown in figure 6A, despite KO hepatocytes were 
constitutively insulin resistant, IL-1β is able to inhibit hepatocyte AKT phosphorylation 
in response to insulin (50 nM). In addition, we analyzed the expression of IRS1 and we 
observed that IL-1β treatment reduced total IRS1 levels in WT and KO isolated 
hepatocytes, although this reduction is more significant in the KO genotype (Figure 
6B). In these conditions, AKT protein activation is diminished in hepatocytes from KO 
mice probably due to the ability of IL-1β to diminish IRS1 protein levels. Then, we 
analyzed the effect of IL-1β treatment in the induction of caspase-3 activity as a 
measured of cell death. After IL-1β stimulus, we observed an increase in caspase-3 
activity only in hepatocytes isolated from KO mice (Figure 6C). These results could 
explain the modifications observed in the in vivo studies of the apoptotic and insulin 
signaling pathways, suggesting a more sensitive response in KO liver mice to IL-1 
action. 
3.7 TNFR1 disruption drives the progression from simple steatosis to a more severe 
stage of NAFLD in a HFD 
To investigate if the augmented inflammation, insulin resistance and hepatocyte 
apoptosis observed in KO-HF-fed mice was accompanied by increased hepatic fibrosis, 
a predominant feature of advanced NASH, we assessed the liver architecture for the 
evaluation of hepatic collagen deposition in HF-fed mice. Whereas fibrosis was absent 
in HF-fed-WT mice, we observed mild fibrosis by Sirius Red and Masson’s Trichrome 
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staining of liver sections in HF-fed-KO mice (Figure 7A). Figure 7B shows the fibrosis 
score in HF-fed mice assessed through histological analysis, while Figure 7C represents 
collagen content in these HF-fed groups measured by Sirius Red staining. In figures 7B 
and C we observed the same increase in these parameters in KO mice with respect to 
WT fed with high fat diet.Ours results showed that KO phenotype under HFD exhibited 
inflammation and bile duct proliferation mainly in portal zone. These results indicate 
that disruption of TNFR1 signaling promotes liver damage and the progression from 
simple steatosis towards a more severe liver disease phenotype in mice feeding with 
HFD. 
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4. DISCUSSION 
Obesity, insulin resistance and its associated complications are increasing 
dramatically and have become an important global health issue. The incomplete 
understanding of the pathological mechanism of these diseases is the reason why the 
therapeutic strategies remain unsatisfactory. 
Little is known about the role of TNFR1 signaling in the development of obesity, 
insulin resistance and liver damage. Here, we aimed to gain more knowledge about the 
biological significance of TNFR1 deletion in the development of insulin resistance and 
in the progression of steatohepatitis using a “loss of function” murine model. In this 
study we found that disruption of TNFR1 signaling increases plasma IL-1β levels, 
exacerbates liver obesity-related inflammatory response, insulin resistance, and liver 
damage in mice fed with a HFD. 
Chronic HFD treatment causes accumulation of lipids in the liver, a process 
leading to fatty liver disease [19]. Under these nutritional conditions, HFD-KO mice 
developed more severe steatosis, including higher accumulation of lipid vacuoles and a 
significant increase in liver triglycerides (TG) content than HFD-WT. In addition, ALT 
and AST activities significantly correlated with liver injury. It was previously reported 
in mutant mice expressing non-sheddable TNFR1s (p55
ns/ns
), which exhibit persistent 
expression of the receptor at the cell surface, that TNFR1 constitutive signaling is not 
associated to the development of hepatic steatosis. Even more, advanced NASH-like 
phenotypes were observed in the livers of these mutant mice fed a HFD compared to 
wild type mice, suggesting a possible role of TNFR1 during the progression of NAFLD 
pathogenesis [12]. In the other hand, and confirming the key role of TNFR1 in NAFLD 
progression and NASH pathogenesis, we observed that the deletion of TNFR1 in obese 
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mice leads to an exacerbation of liver steatosis and inflammation suggesting a cross-talk 
between the TNFR1 and liver lipid accumulation as an important mediator in the 
pathophysiology of NASH. 
Hepatic resident macrophages or Kupffer cells (KC) are central players in the 
development of NAFLD, by secreting pro-inflammatory cytokines, recruiting other 
inflammatory immune cells and so promoting hepatic inflammation and insulin 
resistance. In the present work, we found that the lack of TNFR1 enhanced liver 
inflammation. To define the characteristics of innate immune cells, we isolated NPCs 
from obese mice and found that livers from TNFR1-KO mice showed an increase in 
CD45
+
F480
+
 cells under fat fed condition, suggesting macrophage hepatic accumulation 
in this genotype. Despite the KCs classical activation pathways, it can be directly 
activated by cytokines, adipokines or free fatty acids secreted from adipose tissue which 
induce the polarization of KCs to the pro-inflammatory M1 phenotype. In this regard, 
the analysis of CD45
+
/F480
+
 population revealed an increase in the number of 
CD45
+
F4/80
+
CD11c
+
 cells in mice lacking TNFR1 fed with high fat diet, a feature 
associated with NASH progression [27] and with a pro-inflammatory M1 state [20]. The 
exacerbated release of M1 Kupffer-cell-derived mediators contributes to the 
pathogenesis of liver steatosis, the recruitment of inflammatory immune cells, and the 
activation of fibrotic process [28]. In line with this, ours results demonstrated, for the 
first time, that TNFR1 disruption not only leaded to an impaired inflammatory profile of 
liver resident macrophage, but also to an increased hepatic macrophage recruitment, 
suggested by an exacerbated number of CCR2-expressings cells. 
Because NAFLD and insulin resistance are associated pathologies, we tested 
whether the chronic, low-grade inflammation and liver damage observed in HF-fed-KO 
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mice contributed to the development of insulin resistance. Although those mice showed 
a diminished weight gain and normal systemic sensitivity to insulin, they were able to 
develop intrahepatic insulin resistance. In these sense and in accordance with ours 
results, others authors reported that MCD-fed mice exhibited lost enhanced glucose 
tolerance and insulin hypersensitivity [29,30]. We hypothesized that, TNFR1-KO mice 
behaves as MCD-diet mice  when are subjected to HFD, probably as a consequence of 
hepatic steatosis and inflammation that may lead to hepatic resistance, by a direct 
interference with effectors of intracellular IR-dependent signaling pathways. Other 
studies provide evidence for the possibility that liver insulin resistance is dependent on 
autocrine and paracrine actions of IL-1β [31]. Our results demonstrated that plasmatic 
levels of IL-1β were increased in WT mice fed a HFD. To date, little is known on the 
pro-inflammatory cytokine profile in mice lacking TNFR1 fed a HFD. We found that, 
the disruption of TNFR1 induces a 7-fold increase in plasma IL-1β levels in HF-fed-KO 
mice, indicating that the lack of the receptor somehow is implicated in the deregulation 
of cytokine production. Moreover, pro-inflammatory mRNA markers were also higher 
in hepatic tissue from HF-fed-KO mice when compared to WT mice after HFD. In a 
recent study, it was reported that following LPS exposure, TNFα KO mice produce 
three times the amount of IL-1β compared to WT mice, suggesting a cross-talk in of this 
cytokines pathways [32]. The activation of TLR4 signaling leads to the generation of 
pro-inflammatory cytokines, including IL-1β, through the up-regulation of several 
transcription factors. Interestingly, we observed an increase in TLR4 expression HFD-
KO mice in association with the excess of inflammatory macrophages, the mRNA 
expression, and the rise of plasmatic levels of IL-1β. According to our results, we 
suggest that disruption of TNFR1 leads to an increased number of KCs after a HFD 
which could contribute to amplify the hepatic inflammatory response through the 
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activation of TLR4 signaling. Additionally, all these pro-inflammatory mediators might 
be able to lead to hepatic toxicity and impairment of liver function. 
In classical immune response, IL-1β is more frequently viewed to exert local 
cell-cell, rather than systemic effects, suggesting that it is more likely involved in 
paracrine (and/or autocrine) interactions rather than mediating endocrine 
communication [31]. In this sense, HFD-KO mice showed a higher expression of IL-1β 
receptor in plasma membrane of hepatocytes, suggesting that IL-1β synthesis may take 
place in the liver and once released, mature IL-1β is able to bind to hepatocyte 
receptors. The potential of the liver as a metabolic target for IL-1β in obesity could be 
inferred from the finding that the IL-1 receptor a (IL-1Ra) antagonist not only improved 
stimulated insulin levels, but also decreased fasting glucose, largely reflecting 
attenuated hepatic glucose production [33]. The results obtained in our study 
demonstrated that the disruption of TNFR1 induces a higher increase of plasmatic IL-1β 
that is correlated with an augmented expression of its hepatic mRNA levels. 
Furthermore, when TNFR1-KO animals were feeding with a High Fat Diet there was an 
exacerbated rise of plasmatic IL-1 concomitantly with an impairment of hepatic 
insulin signaling. This phenomenon was also examined and observed in isolated 
hepatocytes. KO hepatocytes were constitutively insulin resistant, probably as a 
consequence of endogenous IL-1 levels in CHOW-KO mice. Otherwise, taken 
together, our in vitro studies allow us to hypothesize an IL-1 effect over hepatic insulin 
resistance exacerbated in KO hepatocytes, which is due in part to the impairment of 
AKT activation and the reduction of IRS1 protein levels. 
In line with the notion that insulin exerts anti-apoptotic functions in many cell 
types, [34], in a previous work we demonstrated that hepatic insulin resistance was 
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associated with the apoptotic process [19]. Here, our results showed that HFD-KO mice 
exhibited an increased apoptotic process in the liver. In addition, in a study performed 
in liver biopsy of patient with NASH, it has been reported a positive correlation 
between the hepatic mRNA levels of IRS1, IRS2, p85a, and anti-apoptotic mediators, 
indicating that impairment of the hepatic insulin signaling pathway is closely related to 
enhanced hepatocyte apoptosis in NASH [24]. A large body of evidence has shown the 
mediation by AKT in the anti-apoptotic action of insulin in a variety of cell types [35–
37]. AKT is required to maintain the pro-apoptotic protein BAD inactive [38]. 
Phosphorylated BAD is sequestered away from the site of action in the mitochondria 
[39,40]. In this connection we analyzed mitochondrial BAD localization and we noted 
that HFD-KO mice showed an increase in BAD expression in the mitochondria, 
correlating with a diminution of AKT activation. These results demonstrated that the 
disruption of TNFR1 in mice fed with HFD induces apoptosis in part due to insulin 
resistance and the translocation of BAD to the mitochondria. 
In the other hand, we could not discard a direct effect of IL-1β on the apoptotic 
process. Sustained inflammation can trigger apoptosis and pyroptosis, another form of 
programmed cell death defined as a caspase-1-dependent cell death that is associated 
with the generation IL-1β [41]. We found increased apoptosis both in vivo and in vitro, 
which is associated with increased production of IL-1β and caspase-3 activities. Further 
studies are necessary to determine the implication of inflammosome and pyroptosis in 
TNFR1 KO mice feed with HFD. Overall, these results suggest that IL-1β induces 
apoptosis in the livers of TNFR1 KO mice. It is well documented that IL-1β treatment 
induces a sustained activation of ERK and p38MAPK, which are known to be 
implicated in the induction of the apoptotic process [42], facts also observed in our 
model. 
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Judging for our results that indicated an important role for TNFR1 in the 
progression of NAFLD, we investigated the effect of the deletion of TNFR1 on hepatic 
fibrosis, an advanced hallmark of NASH. We observed increased level of collagen by 
histologic analysis in HF-fed-KO mice when compared to HF-fed-WT mice. According, 
a clinical study demonstrated that hepatic insulin signaling is markedly impaired in 
NASH patients, and downregulation of hepatic insulin mediators is associated with 
enhanced hepatocyte apoptosis and fibrogenesis [24]. In line with this, we demonstrated 
that TNFR1 signaling disruption, in a context of HFD feeding, leads to a progression 
from simple steatosis toward a more serious phenotype with many NASH features, 
including not only inflammation, insulin resistance but also apoptosis and fibrosis. 
4.1 Conclusion 
The present study reveals a critical role for TNFR1 in the development of a 
hepatic metabolic disease. Our findings show for the first time that the disruption of 
TNFR1 signaling causes systemic insulin resistance due to an increased IL-1β 
production, which in turn, induces hepatic lipid accretion and activation of the apoptotic 
machinery, leading to inflammation and the develop of a more severe form of NAFLD. 
This evidences point out a novel functional role for TNFR1 in the pathogenesis and 
progression of NAFLD. 
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FIGURE LEGENDS 
Figure 1. Assessment of diet-induced insulin resistance model and fat liver 
accumulation.  
(A) Body weight was registered periodically for Wild type (WT) (circle) or TNFR1 KO 
(square) mice fed on standard rodent chow (white) or high-fat diet (black).  Initial and 
final body weight and (B) energy intake, determined over the experimental period of 16 
weeks and expressed as Kcal/day. (C) Glucose tolerance test (GTT) after 16 h fasting. 
Graph represents area under the curve (AUC) during GTT, and Insulin Tolerance Test 
(ITT) after 6 h fasting. Graph represent constant of glucose disappearance (Kitt) 
obtained from ITT. (D) Plasma levels of AST and ALT in WT and KO mice fed with 
HFD. (E) Representative images of hematoxylin/eosin (H&E) stained liver slices from 
HFD WT and HFD KO mice (200X). Determination of Steatosis grade according to 
Liang et al. score [43]. (F) Triglycerides content in total liver homogenate. Data are 
expressed as means ± s.e.m (n=4–5 per group). *p<0.05 vs CHOW WT. # p<0.05 vs 
HFD WT. †p<0.05 vs CHOW KO. 
 
Figure 2. TNFR1 KO mice exhibit macrophages liver infiltration under HFD. 
(A) Representative images of H&E stained liver sections taken from HFD WT and HFD 
KO mice (100X), where arrows indicate inflammatory infiltrates, and quantification of 
inflammation score. (B) Analysis of CD45
+
F4/80
+
 isolated non-parenchymal liver cells; 
(C) CD45
+
F4/80
high
 and CD45
+
F4/80
low
 populations. (D) Analysis of CD11c
+
 
population from the CD45
+
F4/80
+
 gated cells in (B). (E) CCR2
+
 population from 
F4/80
+
CD11b
+ 
gated cells. Values are expressed as percentage. Data are expressed as 
means ± s.e.m (n=4-5 per group). # p<0.05 vs HFD WT. 
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Figure 3. TNFR1 disruption attenuated hepatic insulin signaling in mice fed with 
HFD. 
(A) Immunoblot analysis and densitometry of liver lysate p-AKT/AKT ratio in WT and 
TNFR1 KO mice livers upon regular chow or high fat diet feeding; (B) p-IR/IR ratio in 
liver plasmatic membrane enriched fraction and (C) IRS1 immunoblot, densitometric 
analysis in liver lysate and mRNA levels of Irs1 measured in liver and eWAT by real-
time quantitative PCR and normalized to the expression of Gapdh mRNA. Data are 
expressed as mean ± s.e.m (n=4-5 per group). *p<0.05 vs CHOW WT.  # p<0.05 vs 
HFD WT. †p<0.05 vs CHOW KO. (D) p-ERK/ERK ratio in liver lysate. Bar graph 
shows the mean ± s.e.m (n=4-5 per group). Values are expressed as percentage of 
control (CHOW WT). *p<0.05 vs CHOW WT. #p<0.05 vs HFD WT. †p<0.05 vs 
CHOW KO. (E) Isolated hepatocytes from WT and TNFR1 KO mice fed on standard 
rodent chow or high-fat diet were incubated in DMEM/F12 medium with supplements. 
After 4 hours of culture and 2 hours of starving (2% FBS), hepatocytes were stimulated 
with 0, 10 or 50 nM insulin and p-AKT/AKT ratio was analyzed by Western Blot. 
Values are expressed as percentage of control (CHOW WT + Insulin 50 nM). *p<0.05 
vs CHOW WT (insulin 10 nM). †p<0.05 vs CHOW WT (insulin 50 nM). #p<0.05 vs 
HFD KO (insulin 50 nM). 
 
Figure 4. Apoptotic cell death is increased in TNFR1 KO mice. 
(A) Apoptotic cells were estimated by the apoptotic index (AI) assessed in H&E stained 
liver slices (B) Caspase-3 activitiy was evaluated by a fluorometric assay in liver lysates 
from four experimental groups. Bar graphs represent Relative Fluorescence Units 
(RFU) (C) Representative images of apoptotic cells evaluated by TUNEL assay. (D) 
Mitochondrial levels of pro-apoptotic BAX and anti-apoptotic BCL-xL proteins were 
analyzed by Western blot. BAX:BCL-xL ratio was calculated, and results were 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
30 
 
expressed as percentage of control (CHOW WT). (E) Immunoblot and densitometry of 
mitochondrial BAD protein. (F) Measurement of apoptosis of hepatocytes isolated from 
all experimental groups by flow cytometry (percentage of hypodiploid cells). Data are 
expressed as mean ± s.e.m (n=4-5 per group). *p<0.05 vs CHOW WT. # p<0.05 vs HFD 
WT. †p<0.05 vs CHOW KO. 
 
Figure 5. Levels of pro-inflammatory cytokines in plasma, liver and adipose tissues.  
(A) Plasmatic levels of IL-6, IL-1β and TNF-α assessed by Luminex analysis. Values 
are represented as fold increase relative to CHOW WT. (B) mRNA levels of pro-
inflammatory markers measured in liver and (C) in eWAT by real-time quantitative 
PCR and normalized to Gapdh mRNA expression. Immunoblot analysis of IL-1 
Receptor (D) and TLR4 (E) expression in hepatic plasma membrane from all 
experimental groups. Values are expressed as percentage of control (CHOW WT). Data 
are expressed as mean ± s.e.m (n=4-5 per group). *p<0.05 vs CHOW WT.  # p<0.05 vs 
HFD WT. †p<0.05 vs CHOW KO. 
 
Figure 6. Apoptosis and hepatic insulin resistance in HFD-KO mice are IL-1-
dependent. 
Isolated hepatocytes from WT and TNFR1 KO were incubated in DMEM/F12 medium 
with supplements. Cells were serum starved for 2 h and further stimulated with IL-1β 
(10ng/ml). After 24 hours cells were stimulated 0, 10 or 50 nM insulin for (A) p-
AKT/AKT expression ratio determination. Values represent fold change to WT (insulin 
50 nM without IL-1). (B) Immunoblot and densitometric analysis of IRS1 protein 
level. Values represent percentage of WT without IL-1. (C) Caspase-3 activity was 
evaluated by a fluorometric assay in hepatocytes treated with or without IL-1β (50 
ng/ml). Bar graphs represent Relative Fluorescence Units (RFU). *p<0.05; # p<0.05. 
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Figure 7. TNFR1 signaling disruption increase pro-fibrogenic markers in mice liver 
under HFD.  
(A) Representative images of Masson's trichromic (MTC) and Sirius Red stained liver 
paraffin-embedded sections from HFD WT and HFD KO mice. (B) Quantification of 
fibrosis score. (C) Quantification of collagen content. Expressed as percentage area 
measured in Sirius Red stained slices. Data are expressed as mean ± s.e.m (n=4-5 per 
group). #p<0.05 vs HFD WT. 
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 CHOW WT HFD WT CHOW KO HFD KO 
Glycemia (mg/dl) 96.92 ± 3.12 111.0 ± 3.08 * 90.5 ± 3.08 92.33 ± 6.18 
#
 
Triglycerides (mg/dl) 36.0 ± 4.06 67.0 ± 9.82 * 31.63 ± 3.81 45.18 ± 3.70 
† #
 
Cholesterol (mg/dl) 89.0 ± 2.73 168.1 ± 8.37 * 70.7 ± 2.81 135.9 ± 5.49
 † #
 
Insulin (ng/ml) 0.29 ± 0.03 0.48 ± 0.04 *† 0.33 ± 0.02 0.31 ± 0.01 # 
HOMA-IR (a.u.) 1.05 ± 0.11 1.65 ± 0.14 *† 1.10 ± 0.05 1.11 ± 0.06 # 
 
Table 1. Biochemical and metabolic characteristics of TNFR1 KO mice after HFD. 
Plasma levels of glycemia, triglycerides, cholesterol, insulin and HOMA-IR from WT 
and TNFR1 KO mice fed on standard rodent chow or high-fat diet. Data are expressed 
as means ± s.e.m. for 4-6 mice of each experimental group. *p<0.05 vs CHOW WT. 
#p<0.05 vs HFD WT. †p<0.05 vs CHOW KO. 
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